{"id":2691,"date":"2026-08-25T12:00:00","date_gmt":"2026-08-25T16:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=2691"},"modified":"2026-08-25T19:45:04","modified_gmt":"2026-08-25T23:45:04","slug":"penn-study-documents-decade-long-cd19-car-t-persistence-in-lymphoma","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=2691","title":{"rendered":"Penn Study Documents Decade-Long CD19 CAR-T Persistence in Lymphoma"},"content":{"rendered":"

Institution:<\/strong> University of Pennsylvania · Product:<\/strong> CART19 (4-1BB CD19 CAR-T) · Indication:<\/strong> B-Cell Non-Hodgkin Lymphoma · Publication:<\/strong> Nature Medicine · Date:<\/strong> August 10, 2026<\/p>\n

\"20260825_Penn_CAR_T_Persistence_Consortium_Therapeutic_Indications\"<\/p>\n

Summary<\/h4>\n

A Nature Medicine study documented 4-1BB-costimulated CD19 CAR-T cells up to 10 years after infusion in adults with B-cell non-Hodgkin lymphoma. Among eight evaluable patients who remained in remission beyond five years, the CAR transgene was detectable in five; three patients with higher-level persistence also maintained B-cell aplasia. The work establishes biological feasibility of decade-long persistence in lymphoma, but it does not prove that persistence caused remission, define an optimal persistence threshold, or show that indefinite activity is uniformly desirable.<\/p>\n

What Happened<\/h4>\n

The single-center cohort included 38 adults treated on NCT02030834: 24 with large B-cell lymphoma and 14 with follicular lymphoma. Best overall response rates were 58% and 79%, respectively. At 10.1 years of median follow-up, no relapse occurred beyond 5.4 years; previously reported 10-year lymphoma-free survival was 32% for large B-cell lymphoma and 47% for follicular lymphoma. Twelve patients remained in remission beyond five years, and eight had samples suitable for persistence testing; quantitative PCR detected the CAR transgene in five of those eight at 7.0-10.1 years, though only one patient had a clearly separable CAR-positive population by flow cytometry (1.2% of circulating T cells at year 9.3). In that deeply characterized patient, long-lived CAR-T cells were predominantly CD4-negative\/CD8-negative, activated and effector-memory-like, with aerobic-metabolism, interferon and checkpoint-expression programs. A dominant clone comprised approximately 70% of CAR-positive cells at year 9.3 and was already detectable below 0.1% at day 14; integration-site analysis identified a predominant PACS1 integration without evidence of a known expansion driver.<\/p>\n

Deep Analysis<\/h4>\n

The study provides platform-level validation that a 4-1BB CD19 CAR product can remain molecularly and functionally detectable for a decade in lymphoma, extending long-term persistence observations from leukemia into B-cell lymphoma and identifying a convergent late phenotype, though the multiomic depth is concentrated in one exceptional responder. Persistence is not equivalent to clinical benefit: durable remission may reflect early tumor clearance, host immunity or favorable disease biology, with persisting cells acting as a correlate rather than the cause. Conversely, sustained B-cell aplasia and recurrent infections in the deeply characterized patient show that long-lived activity can carry chronic immune cost even when disease control continues.<\/p>\n

Manufacturing and engineering implications are hypothesis-generating: early rare clones can dominate years later, suggesting that product composition, integration site, antigen exposure and host selection pressures may influence durability. The data do not establish a reproducible release assay, a preferred phenotype at infusion, or superiority of one commercial product.<\/p>\n

Company and Product Background<\/h4>\n

The University of Pennsylvania-led consortium studied CART19, the research product that informed tisagenlecleucel development, in relapsed or refractory B-cell non-Hodgkin lymphoma. CD19 CAR-T cells recognize CD19 on malignant and normal B cells; 4-1BB costimulation is intended to support a memory-associated cellular program and durable expansion. Large B-cell and follicular lymphomas can achieve long remissions after CD19 CAR-T, but relapse may follow antigen escape, inadequate expansion, cellular exhaustion or a hostile microenvironment; persistent target depletion can support surveillance while also causing hypogammaglobulinemia and infection risk, requiring immunoglobulin replacement and antimicrobial management in selected patients.<\/p>\n

Signal Extraction<\/h4>\n\n\n\n\n\n\n\n
Factor<\/th>\nAssessment<\/th>\n<\/tr>\n
Clinical Durability<\/td>\nNo relapses beyond 5.4 years; long-term responders followed to ~10 years<\/td>\n<\/tr>\n
Cell Persistence<\/td>\nCAR transgene detected in 5\/8 evaluable responders beyond year 5<\/td>\n<\/tr>\n
Functional Activity<\/td>\n3 higher-level persisters maintained B-cell aplasia (pharmacodynamic marker + immune burden)<\/td>\n<\/tr>\n
Late Phenotype<\/td>\nDouble-negative, activated effector-memory-like program with ongoing proliferation<\/td>\n<\/tr>\n
Clonal Architecture<\/td>\nA rare day-14 clone became dominant (~70%) at year 9.3; no known driver identified<\/td>\n<\/tr>\n<\/table>\n

Reading the Signal<\/h4>\n

Bull case:<\/strong> Decade-long persistence with functional B-cell aplasia and active late transcriptional programs suggests ongoing biological surveillance rather than inert residual DNA, supporting durable disease control in a meaningful subset of patients.<\/p>\n

Bear case:<\/strong> Persistence was evaluated primarily among survivors, small numbers and responder enrichment limit generalizability, and chronic B-cell aplasia imposes real infection risk that must be weighed against any surveillance benefit.<\/p>\n

InSilens Take<\/h4>\n

This paper establishes that 4-1BB CD19 CAR-T cells can remain active for a decade in lymphoma and identifies a distinctive late cellular state, a rare and valuable mechanistic data point. It does not establish that more persistence is always better, that persistence is necessary for cure, or that the observed phenotype can yet be engineered reproducibly.<\/p>\n

Signal Assessment<\/h4>\n

Importance:<\/strong> 4\/5 · Direction:<\/strong> Mixed · Confidence:<\/strong> High on facts, Moderate on interpretation<\/p>\n","protected":false},"excerpt":{"rendered":"

A Nature Medicine study documented 4-1BB-costimulated CD19 CAR-T cells up to 10 years after infusion in adults with B-cell non-Hodgkin lymphoma. Among eight evaluable patients who remained in remission beyond five years, the CAR…<\/p>\n","protected":false},"author":1,"featured_media":2698,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,3],"tags":[377,55,130],"class_list":["post-2691","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-clinical","category-therapeutic-indication","tag-car-t-cell-therapy-2","tag-follicular-lymphoma","tag-large-b-cell-lymphoma"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2691"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2691\/revisions"}],"predecessor-version":[{"id":2703,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2691\/revisions\/2703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2698"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2691"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2691"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}